Sarcomatoid carcinoma of the pancreas: A case report and review of the literature

  • Authors:
    • Yingjun Xie
    • Yien Xiang
    • Dan Zhang
    • Xiaoxiao Yao
    • Jiyao Sheng
    • Yongsheng Yang
    • Xuewen Zhang
  • View Affiliations

  • Published online on: September 14, 2018     https://doi.org/10.3892/mmr.2018.9489
  • Pages: 4716-4724
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Sarcomatoid carcinoma (SC) is an extremely rare and complicated malignant neoplasm that consists of both malignant epithelial components and atypical spindle cells that express an epithelial phenotype. The presents study reported a case of SC of the pancreas (SCP), along with a brief review of the literature. A 63‑year‑old man was admitted to The Second Hospital of Jilin University hospital with complaints of epigastralgia and jaundice of one month in duration. Based on preoperative laboratory blood tests and radiography, a mass at the distal common bile duct was suspected. Intraoperative examination discovered a 2.5x2x1.8‑cm mass in the pancreatic head, with invasion of the distal bile duct. Pancreaticoduodectomy was performed. Histopathology and immunohistochemistry of the specimen confirmed the diagnosis of SCP. The patient succumbed 18 months after surgery due to multiple hepatic metastases.

Introduction

Sarcomatoid carcinoma (SC) or carcinosarcoma (CS) is a rare and complicated malignant neoplasm that consists of both malignant epithelial components and atypical spindle cells that express an epithelial phenotype (1,2). SC or CS primarily occurs in the lungs, esophagus, breast, larynx, and gallbladder (3). SC of the pancreas (SCP) is extremely rare. Its clinical presentation is similar to that of pancreatic ductal adenocarcinoma. In most cases, the diagnosis is made on histopathological examination of the resected specimen. SCP is associated with poor prognosis. Surgery remains the mainstay of treatment. Due to rarity of the disease, no specific adjuvant therapy is available. Here, we report a patient with obstructive jaundice who was suspected to have distal cholangiocarcinoma and underwent pancreaticoduodenectomy (PD); the SCP diagnosis was made according to a detailed pathological examination.

Case report

A 63-year-old man was admitted to our hospital with the chief complaints of epigastralgia and jaundice of one month's duration. Significant past history included a weight loss of 10 kg in two months and a left nephrectomy due to left renal cancer one year before. Physical examination showed tenderness in the epigastrium. Laboratory blood tests revealed elevated serum liver enzymes levels, including alkaline phosphatase and γ-glutamyl transferase levels. The level of total serum bilirubin was 244 µmol/l (normal range: 5–21 µmol/l), with a direct serum bilirubin of 140 µmol/l. Tumor marker levels were within normal ranges with the exception of mildly elevated CA72-4 levels (10.38 U/ml, normal range: 0.2–6.9 U/ml). Abdominal computed tomography (CT) showed gross dilation of the bile ducts and gallbladder (Fig. 1A) with abrupt narrowing at the distal common bile duct (CBD) (Fig. 1B). Magnetic resonance cholangiopancreatography (MRCP) confirmed the above CT findings (Fig. 1C and D) and showed a beaklike change in the distal CBD (Fig. 1E and F). However, no definite mass lesion was visible. Based on the clinicoradiological findings, distal bile duct cancer was suspected, and the patient was prepared for surgery. Informed written consent was taken from the patient. Because there was no cholangitis, preoperative biliary drainage was not performed. During the surgery, a mass in the pancreatic head, measuring 2.5×2×1.8 cm, was detected without any vascular invasion, and a PD was therefore performed.

Gross examination of the specimen showed a grayish white mass with variegated areas of necrosis and invasion of the distal CBD. Under the microscope, the cut specimen primarily consisted of staggered spindle cells with apparent atypia and frequent mitotic activities (Fig. 2A-C). Pleomorphic giant cells were also observed amid the spindle cells (Fig. 2A-C). However, we also observed some malignant epithelial components, and local invasion of the peripheral nerves. The lymph nodes, blood vessels and resection margins were free from tumor tissue. Immunohistochemistry showed that the spindle cells were positive for vimentin (Fig. 2D), CK7 (Fig. 2E) and CK19 (Fig. 2F). Thus, a diagnosis of SCP was confirmed.

The patient received thymopeptides (1 mg per day) which is extracted from the traditional Chinese medicine for 15 days after surgery, to enhance immunity. His postoperative course was uneventful, and he was discharged from the hospital 10 days after surgery. At 16 months after surgery, the patient was found to have multiple hepatic metastases (Fig. 3). Because the patient's general condition was poor, no chemoradiation was offered. Palliative care and thymopeptides (1 mg twice per week) were given. He died 18 months after surgery.

Discussion

SCP is an exocrine neoplasm that originates from pancreatic ducts and acini (4). The most recent WHO classification of exocrine pancreatic tumors categorizes spindle cell carcinoma, SC and CS under a common heading of undifferentiated (anaplastic) carcinoma (5) because the spindle cells commonly express an epithelial immunohistochemical phenotype and/or genetic alterations in pancreatic ductal adenocarcinoma (6). Although several histogenetic mechanisms have been suggested for SC or CS, the exact mechanism is unclear. One proposed mechanism is that the mesenchymal components of SC include metaplasia from carcinoma under the influence of transforming growth factor beta (TGFβ) (3,7). CS formation is also suggested to occur when a monoclonal stem cell differentiates in two different directions (epithelial and mesenchymal components) under the stimulation of oncogenic factors (3).

SCP is commonly observed in older men with the average age of 60 years and its incidence is twice as high in males as in females according to previous data (4,8,9). We collected and analyzed data from 23 patients with SC or CS of the pancreas (Table I) and found that the average age at diagnosis is 63.30±14.61 years old. However, incidence rates between males and females are almost the same (10 male patients and 13 female patients). The most common symptoms of SCP include epigastralgia, poor appetite, abdominal distension, indigestion, diarrhea and weight loss. Vomiting and hematochezia may occur when the tumor invades the duodenum. Jaundice develops when the tumor infiltrates and obstructs the common bile duct. Tenderness in the epigastrium, with or without a mass, may be found via abdominal palpation. In the present case, the patient had obvious jaundice because of the partial displacement and obstruction of the distal CBD by the tumor.

Table I.

Clinicopathological characteristics of cases of sarcomatoid carcinoma of the pancreas reported in the English literature.

Table I.

Clinicopathological characteristics of cases of sarcomatoid carcinoma of the pancreas reported in the English literature.

Sr. no.Author, yearAge in years/genderTumor locationTumor size in cmUS/EUSCT/enhanced CTMRI/enhanced MRIPTCMRCPERCPTreatmentCarcinomaSarcomatoid componentFollow-up in months/outcome(Refs.)
7De la Riva et al, 200672/femaleVater papillaNA+/-+/+−/−+PapillotomyNot identified, but associated with choledochal with choledochal cystSC; IHC: CK and vimentin (F+)9/succumbed to SC metastatic to the liver(1)
13Kane et al, 201485/malePB3.3×3.0× 2.6−/++/+−/− Distal pancreatectomy, splenectomy and partial gastrectomyPD1 adenoSC; IHC: diffuse pan-CK, CK52, p53 (D+), synaptophysin, chromogranin, calponin, S100, SMA, CK19, MUC1, nuclear β-Catenin, p63, EMA and CD10 (−)26/alive and well(2)
15Ren et al, 201348/malePT9.3× 9.4×7.5+/-+/-−/− NAMD adenoSC; IHC: CK19, vimentin, α-1-antichymot- rypsin (+), CD68 (−)36/alive and well(7)
22Mszyco et al, 201785/malePHNA+/++/+−/−+PD2NANANA(10)
17Lu et al, 201458/femalePT16×18−/−+/++/- Resection of the pancreatic tail, fundus of the stomach and spleenWD squamousSC; IHC: CK7 and vimentin (+)5/alive but hepatic metastases were found(12)
20Jia et al, 201744/femalePH2.9×1.6+/-+/++/- ++PD2MD adenoCS; CK7 and vimentin (+)31/alive and well(13)
6Kim et al, 200673/femalePB, PT20.0× 15.0×13.0−/−+/-−/−Distal pancreatectomy, splenectomy, partial gastrectomy and colectomyPD1 adenoSC, vimentin (D+), CD68 (F+), CK (−)3/succumbed to cachexia with generalized tumor extension(18)
19Lee et al, 201524/femalePT4.7×3.5−/−+/+−/− Distal pancreate-ctomy and splenectomyNACS; CK and vimentin (+)NA(21)
8Gelos et al, 200861/femalePH7×6×3.5−/−+/+−/− PD2MD adenoCS; vimentin (D+), PDGF (F+), Ki-67 (10%+),CD117 and CK(−)11/recurrence(27)
1Cresson et al, 198769/malePH, PTNA−/−−/−−/−Chemotherapy and radiotherapyNACS, tubular structures, desmosomes and hemijunctions under electron microscope5/hemorrhage after jejunum resection(28)
2Higashi et al, 199974/malePH4.5×4.0×3.0+/-+/+−/−+PPPDPD1 adenoSC; IHC: CK AE1, variable CK AE3, EMA, MUC1-ARA (D+), S100, SMA (F+), desmin, vimentin, NSE and CEA (−)3/succumbed to diffuse peritoneal carcinomatosis(29)
3Darvishian et al, 200274/malePH4.0×3.0−/−+/-−/−+PD2MD adenoSC; IHC: vimentin (D+), CK (F+), CEA, SMA, DESMIN and CD68 (−)4/alive and well(30)
4Barkatullah et al, 200567/femalePH2.5×2.5×2.0+/++/-−/−PPPDMD adenoSC, separate focus of OGC; IHC (SC): CK8/18 vimentin (D+)8/NA(31)
5Bloomston et al, 200667/femalePH4×4×3−/−+/-−/−+PPPDPD adeno with a focus of malignant squamous cell carcinomaCS; vimentin (D+), CK, EMA, CD117, S100, SMA and desmin (−)4/metastatic disease of the liver and peritoneum(32)
8Nakano et al, 200882/femalePH18.0× 11.0× 10.0−/−+/+−/−+PD2WD adenoSC, foci of OGC around hemorrhage; IHC (SC): vimentin, CD10 (D+), CK AE1/AE3 (F+), CK7, CK20, CEA, EMA, SMA and S100 (−)O/succumbed to DIC on post-operative day 13(33)
10Kim et al, 201148/malePT3.5×2.5 ×1.5−/−+/-+/- Pancreatectomy with splenectomy and colonic segmental resectionMucinous cyst, adeno and anaplastic carcinomaSC, scattered OGC; IHC (SC): vimentin (D+), pan-CK, CK7, CK8/18, EMA, CEA, CD34, CD56, CD68, CD117, desmin, SMA, myogenin, S100, ER and PR (−)4/succumbed to hepatic and peritoneal metastases(34)
11Shen et al, 201072/femalePH5×4×4+/-+/+−/− PD2, left hepatic lobe resection and local resection of the gastric massPD1 adenoCS; vimentin (D+)2/multiple metastatic masses in the whole liver and recurrence at tail of the pancreas(35)
12Zhu et al, 201253/femalePH5×4×3+/-−/−+/- PD2PD1 adenoCS; SMA (D+), CK18, EMA, and S-100 (−)20/NA(36)
14Yao et al, 201348/malePT10.0× 8.0×5.0+/-+/-−/− Spleen-preserving left pancreatectomyPD1 adenoSC; IHC: CK (D+), vimentin (−)3/succumbed to recurrence(37)
16Oymaci et al, 201366/malePH3.5× 2.0×1.5−/−+/+−/− +PD2MD adenoCS; vimentin (D+) and SMA (F+)20 days/gastrointestinal bleeding complication(38)
18Shi et al, 201574/femalePT9×6×3−/−+/+−/− Distal pancreate-ctomy and splenectomyColumnar mucin-producing epithelial cellsCS; vimentin (D+)NA(39)
21Salibay et al, 201749/femalePTNA−/−−/−−/− Chemotherapy and radiotherapyMD adenoCS; CK AE1+3, CK7, CDX2, CD10, desmin and SMA (+)10/succumbed to disease progression(40)
23Present study63/malePH2.5×2×1.8−/−+/-−/−+PD2MD adenoSC; IHC: CK19, CK7 and vimentin (D+) p53 (50%+), Ki67 (40%+), VEGF, C-erbB-2, K-ras (−)18/succumbed to cachexia with multiple hepatic metastases

[i] Sr. no., serial number; US, ultrasonography; EUS, endoscopic ultrasonography; CT, computed tomography; MRI, magnetic resonance imaging; PTC, percutaneous transhepatic cholangiography; MRCP, magnetic resonance cholangiopancreatography; ERCP, endoscopic retrograde cholangiopancreatography; PH, pancreatic head; PPPD, pylorus preserving pancreatoduodenectomy; PD1, poorly differentiated; PD2, pancreatoduodenectomy; adeno, adenocarcinoma; IHC, immunohistochemistry; CK, cytokeratin; EMA, epithelial membrane antigen; MUC1-ARA, apoprotein MUC1; (D+), diffusely positive; SMA, smooth muscle actin; (F+), focal positivity; NSE, neuron-specific enolase; CEA, carcinoembryonic antigen; (−), no positivity; NA, data not available; MD, moderately differentiated; PB, pancreatic body; PT, pancreatic tail; OCG, osteoclastic giant cells; WD, well-differentiated; DIC, disseminated intravascular coagulopathy; ER, estrogen receptor protein; PR, progesterone receptor protein.

Many imaging examinations are helpful for the diagnosis of SCP. Ultrasonography (US) is a convenient, noninvasive method for the initial screening of pancreatic tumors. SCP shows a low or mixed echo with a well-defined margin under US. Some indirect signs, such as the dilation of the common bile duct, may also be seen. However, disturbance of gas in the stomach and intestines limits US in diagnosing SCP. Endoscopic ultrasonography (EUS) overcomes this defect of US, with higher imaging resolution and diagnostic accuracy. Fine needle aspiration may also be performed during EUS, for biopsies, which are crucial for the preoperational diagnosis of SCP.

CT and enhanced CT are also widely used. SCP shows several manifestations on CT images. First, SCP primarily occurs in the pancreatic head and tail with an average diameter of 7.20±5.44 cm, according to our data (pancreatic head: n=13, tail: n=9, body: n=2; papilla: n=1; Table I). Pancreatic head SCP can cause slight to moderate obstruction of the bile and pancreatic ducts. No atrophy of the pancreatic tail occurs. Second, nonenhanced CT images show well-circumscribed, hypodense or heterogeneous masses with cystic or solid lesions (10). Third, necrosis often occurs due to insufficient vessels and a solid-cystic mixed SCP structure (11). Fourth, small nodules of calcification may be observed in SCP. Fifth, enhanced CT images may show heterogeneous enhancement in the peripheral solid part of SCP, while the internal unilocular cystic part is often not enhanced (10). Last, due to tumor invasion, the peripancreatic lymph nodes, splenic artery, adjacent duodenum, liver and colon may be displaced and partly or entirely destroyed. In the present case, the small mass (which was invading the bile duct) was not clearly shown by radiography; however, the dilation of the bile ducts and gallbladder provided indirect evidence for the tumor. In magnetic resonance imaging (MRI), SCP shows abnormal signals, such as high or low signals in T2 weighted imaging (12,13). Enhanced MRI is valuable for estimating the extent of local malignant involvement. Together with CT, MRI can clearly increase the diagnostic rate of pancreatic neoplasms, while preventing unnecessary injury during surgery by providing comprehensive imaging. Percutaneous transhepatic cholangiography (PTC) can clearly display the degree of bile duct dilation, thus facilitating diagnosis of pancreatic-head neoplasms. However, this invasive examination could be replaced by a noninvasive technique: MRCP, which provides a comprehensive display of the bile and pancreatic ducts at different levels. In the present case, dilation of the bile and pancreatic ducts indirectly indicated the existence of a periampullary tumor. Endoscopic retrograde cholangiopancreatography (ERCP) not only provides clear observation of periampullary neoplasms under direct vision, but also shows the dilation extent of the pancreatic and bile ducts through injection of contrast medium. Furthermore, tumors can be biopsied after papillotomy, thus providing important pre-surgical evidence for the diagnosis of SCP.

Histologically, SC consists of both malignant epithelial and mesenchymal components (14,15), primarily mesenchymal components. The epithelial components can be adenocarcinoma or squamous cell carcinoma. According to our data (Table I), adenocarcinoma is the most common type (poorly differentiated: n=7, moderately differentiated: n=8, well-differentiated: n=2). Intersecting bundles of spindle cells with apparent atypia and frequent mitotic activities constituted the mesenchymal components. Ordinarily, the proportion of the sarcomatoid part should be greater than 50% to receive a diagnosis of SC (16). A study by Alguacil-Garcia classified SC into four histological subtypes based on light microscopy (4): (a) spindle cell carcinoma, (b) osteoclastic giant cell tumors, (c) pleomorphic giant cell carcinoma, and (d) round cell anaplastic carcinoma. Additionally, some SC specimens show sarcomatoid constituents in metastasized lymph nodes, which show the tumorous nature of the sarcomatoid region rather than reacting hyperplasia of the tissue.

Immunohistochemistry, electron microscopy and genetic studies are of great value in diagnosing SC. Generally, the mesenchymal components of SC express both mesenchymal and epithelial markers, which is critical for SC diagnosis. In the present case, the neoplasm primarily consisted of spindle cells with few epithelial components; however, expression of both mesenchymal and epithelial markers of the spindle cells supported a diagnosis of SC. Vimentin is the most common mesenchymal marker. Other myogenic markers (such as SMA, actin, desmin and myoglobin), neurogenic markers and osteogenic markers may also be positive in related components. Among epithelial markers, CK and EMA may be expressed in epithelial and/or sarcomatoid regions. Electron microscopy may show chitin mother cell granules, tonofibrils, desmosomes and melanin granules in SC spindle cells (17). Among genetic studies, p53 overexpression in both components of SC was found in a Korean case report (18). Furthermore, Almoguera found a KRAS mutation at codon 12 of exon 2 in spindle cells of two SCP cases (19). The identical genetic mutation of epithelial and mesenchymal components provides strong evidence for an EMT mechanism.

Radical resection of the neoplasm is the primary treatment for SCP (20). PD and pylorus-preserving PD (PPPD) are the major procedures for SCP of the pancreatic head, whereas SCP of the pancreatic body and tail is commonly treated with partial resection of the pancreas with splenectomy. Chemotherapy is necessary for cases with metastases in the lymph nodes (3). The prognosis of SCP is extremely poor (2123) and may be associated with the tumor's volume and histological type, and the extent of local lymph node metastases. The average life expectancy is 2–3 months (24,25), with a 3-year survival rate of less than 3% (26). According to a report by Gelos, the average post-operative survival interval was 6 months and the longest living patient survived for 15 months (27). According to our statistics of SCP reported in English literature (Table I), the average post-operative survival of SCP is 10.15±10.23 months. In this case, the patient lived for 18 months after surgery, which suggests that early, radical surgery extends survival for patients with SCP.

SCP is extremely rare, and its clinical presentation is similar to that of pancreatic ductal adenocarcinoma. Diagnosis is made on histopathological examination of the resected specimen. SCP has a poor prognosis, and is primarily treated with surgery; no specific adjuvant therapy is available.

Acknowledgements

The authors would like to thank Mrs Zhehui Wang for providing the pathological section and associated figure legends.

Funding

The present study was supported by grants from the Finance Department of Jilin Province (grant nos. SCZSYZ01502, SCZSYZ01521 and SCZSYZ01522).

Availability of data and materials

The datasets used during the present study are available from the corresponding author on reasonable request.

Authors' contributions

YJX and YX designed the study and wrote the manuscript. YY and XZ contributed to the manuscript revision. DZ, XY and JS contributed to the collection of clinical information and associated literature of SCP.

Ethics approval and consent to participate

The research was approved and consented by the Ethics Committee of the Second Hospital of Jilin University.

Patient consent for publication

The written consent to publish was obtained from the patient.

Competing interests

The authors declare that they have no competing interests.

Glossary

Abbreviations

Abbreviations:

SC

sarcomatoid carcinoma

CS

carcino-sarcoma

SCP

sarcomatoid carcinoma of the pancreas

PD

pancreaticoduodenectomy

CT

computed tomography

CBD

common bile duct

MRCP

magnetic resonance cholangiopancreatography

TGFβ

transforming growth factor beta

US

ultrasonography

EUS

endoscopic ultrasonography

MRI

magnetic resonance imaging

PTC

percutaneous transhepatic cholangiography

ERCP

endoscopic retrograde cholangiopancreatography

PPPD

pylorus-preserving PD

References

1 

De la Riva S, Muñoz-Navas MA, Betés M, Súbtil JC, Carretero C and Sola JJ: Sarcomatoid carcinoma of the pancreas and congenital choledochal cyst. Gastrointest Endosc. 64:1005–1006. 2006. View Article : Google Scholar : PubMed/NCBI

2 

Kane JR, Laskin WB, Matkowskyj KA, Villa C and Yeldandi AV: Sarcomatoid (spindle cell) carcinoma of the pancreas: A case report and review of the literature. Oncol Lett. 7:245–249. 2014. View Article : Google Scholar : PubMed/NCBI

3 

Fang XH: New arguments on carcinosarcoma (CS) and sarcomatoid carcinoma (SC). Cancer Res Clinic. 17:138–139. 2005.(In Chinese).

4 

Alguacil-Garcia A and Weiland LH: The histologic spectrum, prognosis, and histogenesis of the sarcomatoid carcinoma of the pancreas. Cancer. 39:1181–1189. 1977. View Article : Google Scholar : PubMed/NCBI

5 

Fukushima N, Hruban RH and Kato Y: Ductal adenocarcinoma variants and mixed neoplasms of the pancreas. WHO Classific Tumors Digest System. 1–299. 2010.

6 

Hruban RH, Pitman MB and Klimstra DS: Adenocarcinoma variantsTumors of the Pancreas. (AFIP Atlas of Tumor Pathology: Series 4). American Registry of Pathology; Washington, DC: pp. 165–190. 2007

7 

Ren CL, Jin P, Han CX, Xiao Q, Wang DR, Shi L, Wang DX and Chen H: Unusual early-stage pancreatic sarcomatoid carcinoma. World J Gastroenterol. 19:7820–7824. 2013. View Article : Google Scholar : PubMed/NCBI

8 

Shirobe T, Yamamoto T and Mori T: A case of spindle cell carcinoma of the pancreas. Suizo. 10:387–392. 1995.

9 

Wolfman NT, Karstaedt N and Kawamoto EH: Pleomorphic carcinoma of the pancreas: Computed-tomographic, sonographic, and pathologic findings. Radiology. 154:329–332. 1985. View Article : Google Scholar : PubMed/NCBI

10 

Mszyco S, Teng L, Annunziata J and Hartman MS: Pancreatic carcinosarcoma: A case report highlighting computed tomography characteristics. Curr Probl Diagn Radiol. 46:342–345. 2017. View Article : Google Scholar : PubMed/NCBI

11 

Husain AN, Colby TV, Ordóñez NG, Krausz T, Borczuk A, Cagle PT, Chirieac LR, Churg A, Galateau-Salle F, Gibbs AR, et al: Guidelines for pathologic diagnosis of malignant mesothelioma: A consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 133:1317–1331. 2009.PubMed/NCBI

12 

Lu BC, Wang C, Yu JH, Shen ZH and Yang JH: A huge adenosquamous carcinoma of the pancreas with sarcomatoid change: An unusual case report. World J Gastroenterol. 20:16381–16386. 2014. View Article : Google Scholar : PubMed/NCBI

13 

Jia Z, Zhang K, Huang R, Zhou X and Jiang L: Pancreatic carcinosarcoma with rare long-term survival: Case report and review of the literature. Medicine (Baltimore). 96:e59662017. View Article : Google Scholar : PubMed/NCBI

14 

Yu W, Wang Y, Jiang Y, Zhang W and Li Y: Distinct immunophenotypes and prognostic factors in renal cell carcinoma with sarcomatoid differentiation: A systematic study of 19 immunohistochemical markers in 42 cases. BMC Cancer. 17:2932017. View Article : Google Scholar : PubMed/NCBI

15 

Inoue H, Takahashi H, Hashimura M, Eshima K, Akiya M, Matsumoto T and Saegusa M: Cooperation of Sox4 with β-catenin/p300 complex in transcriptional regulation of the Slug gene during divergent sarcomatous differentiation in uterine carcinosarcoma. BMC Cancer. 16:532016. View Article : Google Scholar : PubMed/NCBI

16 

Ding HY and Liao SL: Carcinosarcoma (CS) and sarcomatoid carcinoma (SC). Chin J Diagn Pathol. 6:56–57. 1999.(In Chinese).

17 

Lichtiger B, Mackay B and Tessmer CF: Spindle-cell variant of squamous carcinoma. A light and electron microscopic study of 13 cases. Cancer. 26:1311–1320. 1970. View Article : Google Scholar : PubMed/NCBI

18 

Kim KH, Kang DY, Lee MK, Yang HW and Han HY: Sarcomatoid carcinoma of the pancreas: A case report. Kor J Pathol. 40:306–310. 2006.

19 

Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N and Perucho M: Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell. 53:549–554. 1988. View Article : Google Scholar : PubMed/NCBI

20 

Dall'Oglio MF, Lieberknecht M, Gouveia V, Sant'Anna AC, Leite KR and Srougi M: Sarcomatoid differentiation in renal cell carcinoma: Prognostic implications. Int Braz J Urol. 31:10–16. 2005. View Article : Google Scholar : PubMed/NCBI

21 

Lee J, Hyun JJ and Lee HS: A Rare cause of abdominal pain by pancreatic mass in a young female patient. Carcinosarcoma of the pancreas. Gastroenterology. 149:e3–e5. 2015. View Article : Google Scholar : PubMed/NCBI

22 

Goto T, Hirotsu Y, Mochizuki H, Nakagomi T, Oyama T, Amemiya K and Omata M: Stepwise addition of genetic changes correlated with histological change from ‘well-differentiated’ to ‘sarcomatoid’ phenotypes: A case report. BMC Cancer. 17:652017. View Article : Google Scholar : PubMed/NCBI

23 

Schaefer IM, Sahlmann CO, Overbeck T, Schweyer S and Menke J: Blastomatoid pulmonary carcinosarcoma: Report of a case with a review of the literature. BMC Cancer. 12:4242012. View Article : Google Scholar : PubMed/NCBI

24 

Kurihara K, Nagai H, Kasahara K, Kawai T, Saito K and Kanazawa K: Pleomorphic carcinoma of the pancreas with massive lymphocytic stromal infiltration and long-term survival after resection. Int J Pancreatol. 27:241–248. 2000. View Article : Google Scholar : PubMed/NCBI

25 

Tschang TP, Garza-Garza R and Kissane JM: Pleomorphic carcinoma of the pancreas: An analysis of 15 cases. Cancer. 39:2114–2126. 1977. View Article : Google Scholar : PubMed/NCBI

26 

Kamisawa T, Tabata I, Isawa T, Tsuruta K, Okamoto A and Koike M: A case of pleomorphic carcinoma of the pancreas showing sequential histological change by immunohistochemical study. Int J Pancreatol. 18:67–70. 1995.PubMed/NCBI

27 

Gelos M, Behringer D, Philippou S and Mann B: Pancreatic carcinosarcoma. Case report of multimodal therapy and review of the literature. JOP. 9:50–55. 2008.PubMed/NCBI

28 

Cresson DH and Reddick RL: Sarcomatoid carcinoma of the pancreas presenting as gastric carcinoma: Clinicopathologic and ultrastructural findings. J Surg Oncol. 36:268–274. 1987. View Article : Google Scholar : PubMed/NCBI

29 

Higashi M, Takao S and Sato E: Sarcomatoid carcinoma of the pancreas: A case report with immunohistochemical study. Pathol Int. 49:453–456. 1999. View Article : Google Scholar : PubMed/NCBI

30 

Darvishian F, Sullivan J, Teichberg S and Basham K: Carcinosarcoma of the pancreas: A case report and review of the literature. Arch Pathol Lab Med. 126:1114–1117. 2002.PubMed/NCBI

31 

Barkatullah SA, Deziel DJ, Jakate SM, Kluskens L and Komanduri S: Pancreatic carcinosarcoma with unique triphasic histological pattern. Pancreas. 31:291–292. 2005. View Article : Google Scholar : PubMed/NCBI

32 

Bloomston M, Chanona-Vilchis J, Ellison EC, Ramirez NC and Frankel WL: Carcinosarcoma of the pancreas arising in a mucinous cystic neoplasm. Am Surg. 72:351–355. 2006.PubMed/NCBI

33 

Nakano T, Sonobe H, Usui T, Yamanaka K, Ishizuka T, Nishimura E and Hanazaki K: Immunohistochemistry and K-ras sequence of pancreatic carcinosarcoma. Pathol Int. 58:672–677. 2008. View Article : Google Scholar : PubMed/NCBI

34 

Kim HS, Joo SH, Yang DM, Lee SH, Choi SH and Lim SJ: Carcinosarcoma of the pancreas: A unique case with emphasis on metaplastic transformation and the presence of undifferentiated pleomorphic high-grade sarcoma. J Gastrointestin Liver Dis. 20:197–200. 2011.PubMed/NCBI

35 

Shen ZL, Wang S, Ye YJ, Wang YL, Sun KK, Yang XD and Jiang KW: Carcinosarcoma of pancreas with liver metastasis combined with gastrointestinal stromal tumour of the stomach: Is there a good prognosis with the complete resection? Eur J Cancer Care (Engl). 19:118–123. 2010. View Article : Google Scholar : PubMed/NCBI

36 

Zhu WY, Liu TG and Zhu H: Long-term recurrence-free survival in a patient with pancreatic carcinosarcoma: A case report with a literature review. Med Oncol. 29:140–143. 2012. View Article : Google Scholar : PubMed/NCBI

37 

Yao J, Qian JJ, Zhu CR, Bai DS and Miao Y: Laparoscopic left pancreatectomy for pancreatic sarcomatoid carcinoma: A case report and review of the literature. Oncol Lett. 6:568–570. 2013. View Article : Google Scholar : PubMed/NCBI

38 

Oymaci E, Argon A, Coşkun A, Uçar AD, Carti E, Erkan N and Yildirim M: Pancreatic carcinosarcoma: Case report of a rare type of pancreatic neoplasia. JOP. 14:212–215. 2013.PubMed/NCBI

39 

Shi HY, Xie J and Miao F: Pancreatic carcinosarcoma: First literature report on computed tomography imaging. World J Gastroenterol. 21:1357–1361. 2015. View Article : Google Scholar : PubMed/NCBI

40 

Salibay CJ, Rewerska J, Gupta S and Ree N: Primary carcinosarcoma of the pancreas with CD10-positive sarcoma component. J Investig Med High Impact Case Rep. 5:23247096177409062017.PubMed/NCBI

Related Articles

Journal Cover

November-2018
Volume 18 Issue 5

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Xie Y, Xiang Y, Zhang D, Yao X, Sheng J, Yang Y and Zhang X: Sarcomatoid carcinoma of the pancreas: A case report and review of the literature. Mol Med Rep 18: 4716-4724, 2018.
APA
Xie, Y., Xiang, Y., Zhang, D., Yao, X., Sheng, J., Yang, Y., & Zhang, X. (2018). Sarcomatoid carcinoma of the pancreas: A case report and review of the literature. Molecular Medicine Reports, 18, 4716-4724. https://doi.org/10.3892/mmr.2018.9489
MLA
Xie, Y., Xiang, Y., Zhang, D., Yao, X., Sheng, J., Yang, Y., Zhang, X."Sarcomatoid carcinoma of the pancreas: A case report and review of the literature". Molecular Medicine Reports 18.5 (2018): 4716-4724.
Chicago
Xie, Y., Xiang, Y., Zhang, D., Yao, X., Sheng, J., Yang, Y., Zhang, X."Sarcomatoid carcinoma of the pancreas: A case report and review of the literature". Molecular Medicine Reports 18, no. 5 (2018): 4716-4724. https://doi.org/10.3892/mmr.2018.9489